NEOS - Neos Therapeutics, Inc.
| Previous Close | 1.6000 |
| Open | 1.6100 |
| Bid | 1.6900 x 1800 |
| Ask | 1.7200 x 800 |
| Day's Range | 1.5900 - 1.8500 |
| 52 Week Range | 1.1300 - 3.6200 |
| Volume | 453,647 |
| Avg. Volume | 194,958 |
| Market Cap | 85.54M |
| Beta (5Y Monthly) | 0.94 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4770 |
| Earnings Date | Nov 07, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.75 |
- GlobeNewswire
Neos Therapeutics Initiates and Completes Dosing in a Phase 1 Trial of NT0502 for the Treatment of Chronic Sialorrhea
Neos Therapeutics, Inc. (NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today announced that it has initiated and completed dosing in a Phase 1 pilot pharmacokinetic study evaluating the safety and tolerability of NT0502 in healthy volunteers. NT0502 is a new chemical entity and selective anticholinergic agent that, based on preclinical data, is preferential for blocking muscarinic receptors in the salivary glands. The Company is developing NT0502 for the treatment of chronic sialorrhea, which is defined as prevalent and excessive drooling from the mouth resulting from the inability to control and swallow oral secretions, a common problem in patients with a variety of debilitating neurological conditions.
- Simply Wall St.
If You Had Bought Neos Therapeutics (NASDAQ:NEOS) Stock Three Years Ago, You'd Be Sitting On A 77% Loss, Today
As an investor, mistakes are inevitable. But really big losses can really drag down an overall portfolio. So spare a...
- Insider Monkey
Do Hedge Funds Love Neos Therapeutics Inc (NEOS)?
The first quarter was a breeze as Powell pivoted, and China seemed eager to reach a deal with Trump. Both the S&P 500 and Russell 2000 delivered very strong gains as a result, with the Russell 2000, which is composed of smaller companies, outperforming the large-cap stocks slightly during the first quarter. Unfortunately sentiment shifted […]
- Thomson Reuters StreetEvents
Edited Transcript of NEOS earnings conference call or presentation 8-Nov-19 1:30pm GMT
Q3 2019 Neos Therapeutics Inc Earnings Call
- GlobeNewswire
Neos Therapeutics Reports Third Quarter 2019 Financial Results
DALLAS and FORT WORTH, Texas, Nov. 08, 2019 -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company utilizing its novel microparticle delivery.
- GlobeNewswire
Neos Therapeutics to Host Third Quarter 2019 Financial and Operating Results Conference Call on November 8, 2019
DALLAS and FORT WORTH, Texas, Nov. 01, 2019 -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company utilizing its novel microparticle delivery.
- Simply Wall St.
What Kind Of Share Price Volatility Should You Expect For Neos Therapeutics, Inc. (NASDAQ:NEOS)?
If you're interested in Neos Therapeutics, Inc. (NASDAQ:NEOS), then you might want to consider its beta (a measure of...
- GlobeNewswire
Neos Therapeutics to Present at Cantor Fitzgerald Global Healthcare Conference
DALLAS and FORT WORTH, Texas, Sept. 25, 2019 -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company utilizing its novel microparticle delivery.
- GlobeNewswire
Neos Therapeutics to Present at Two Upcoming September Conferences
DALLAS and FORT WORTH, Texas, Aug. 29, 2019 -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company utilizing its novel microparticle delivery.
- Thomson Reuters StreetEvents
Edited Transcript of NEOS earnings conference call or presentation 8-Aug-19 12:30pm GMT
Q2 2019 Neos Therapeutics Inc Earnings Call
- Zacks
Neos Therapeutics (NEOS) Reports Q2 Loss, Misses Revenue Estimates
Neos Therapeutics (NEOS) delivered earnings and revenue surprises of 50.00% and -6.33%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Neos Therapeutics Reports Second Quarter 2019 Financial Results
– Company to host conference call today at 8:30am EDT – DALLAS and FORT WORTH, Texas, Aug. 08, 2019 -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage.
- GlobeNewswire
Neos Therapeutics to Host Second Quarter 2019 Financial and Operating Results Conference Call on August 8th, 2019
DALLAS and FORT WORTH, Texas, Aug. 01, 2019 -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing.
- Zacks
Acer Shares Down on FDA's CRL for Genetic Disorder Treatment
Acer Therapeutics Inc. (ACER) receives a Complete Response Letter from the FDA regarding its new drug application for Edsivo for the treatment of vascular Ehlers-Danlos syndrome.
- GlobeNewswire
Neos Therapeutics to Present at Two Upcoming June Conferences
DALLAS and FORT WORTH, Texas, June 12, 2019 -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing.
- GlobeNewswire
Neos Therapeutics to Present at the Jefferies 2019 Global Healthcare Conference
DALLAS and FORT WORTH, Texas, May 30, 2019 -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing.
- Zacks
Neos Therapeutics Enters Oversold Territory
Neos Therapeutics has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
- Thomson Reuters StreetEvents
Edited Transcript of NEOS earnings conference call or presentation 9-May-19 12:30pm GMT
Q1 2019 Neos Therapeutics Inc Earnings Call
- Zacks
Neos Therapeutics (NEOS) Reports Q1 Loss, Tops Revenue Estimates
Neos Therapeutics (NEOS) delivered earnings and revenue surprises of 31.82% and 3.06%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press
Neos Therapeutics: 1Q Earnings Snapshot
The Grand Prairie, Texas-based company said it had a loss of 15 cents per share. The pharmaceutical company posted revenue of $14.6 million in the period. The company's shares closed at $2.08. A year ago, ...
- GlobeNewswire
Neos Therapeutics Reports First Quarter 2019 Financial Results
DALLAS and FORT WORTH, Texas, May 09, 2019 -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing.
- GlobeNewswire
Neos Therapeutics to Host First Quarter 2019 Financial and Operating Results Conference Call on May 9th, 2019
DALLAS and FORT WORTH, Texas, May 02, 2019 -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing.
- Zacks
Neos Therapeutics (NEOS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Neos Therapeutics (NEOS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
